NFlection Therapeutics is developing first-in-class MEK inhibitors for the topical treatment of neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway. The company aims to provide targeted therapies that address the unmet medical needs of patients suffering from these RAS-mediated disorders.
Funding
$20M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks are disorders driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway. These conditions often lack targeted therapies, resulting in unmet medical needs for affected patients.
Solution
NFlection Therapeutics develops first-in-class MEK (mitogen-activated protein kinase kinase) inhibitors designed for topical treatment of neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks. By targeting the Ras/Raf/MEK/ERK pathway, the company aims to provide novel therapies that directly address the underlying mechanisms of these RAS-mediated disorders. The topical application allows for targeted drug delivery, potentially minimizing systemic side effects. NFlection's approach focuses on developing treatments that can improve patient outcomes and quality of life.
Target Audience
The primary target audience includes patients suffering from neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks, as well as the physicians who treat these conditions.
Features
- First-in-class MEK inhibitors specifically designed for topical application.
- Targeted treatment of neurofibromatosis type 1.
- Targeted treatment of immunosuppressant-mediated squamous cell carcinoma.
- Targeted treatment of congenital birthmarks such as keratinocytic epidermal nevi and nevi sebacei.
- Aims to inhibit the Ras/Raf/MEK/ERK pathway.